Open Access<p>Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma</p>
Author(s) -
Haiying Wang,
Jiayou Chu,
Peng Zhang,
Jiaqiang Wang,
Yan Zheng,
Shuna Yao,
Zhihua Yao,
Yanyan Liu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s235349
Subject(s) - medicine , neutropenia , adverse effect , leukopenia , oncology , response evaluation criteria in solid tumors , progression free survival , chemotherapy , anemia , progressive disease , maintenance therapy , soft tissue sarcoma , gastroenterology , surgery , soft tissue
Anlotinib, a newly developed oral small-molecule receptor tyrosine kinase inhibitor (TKI), has been shown to have encouraging activity against sarcoma. The purpose of this study was to retrospectively evaluate the safety and clinical efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in advanced/metastatic soft tissue sarcoma (STS) patients in a real-world setting in China.